Soligenix (NSDQ:SNGX) skyrocketed up 89% in premarket trading this morning after announcing today that it entered into an exclusive worldwide licensing agreement with Boston Scientific (NYSE:BSX) for its CoVaccine HT novel vaccine adjuvant for COVID-19. Shares of SNGX were up 12.5% at $1.58 per share in mid-morning trading today as well. Boston Scientific’s BTG Specialty Pharmaceuticals […]
